AOD-9604 and Sildenafil Interaction: What Clinicians and Patients Should Know

What Is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to amino acids 176-191 of human growth hormone, with a tyrosine residue added at the C-terminus. It was originally developed by Metabolic Pharmaceuticals in Australia as an anti-obesity candidate. Early Phase IIb trial data (N=300) showed modest fat reduction over 12 weeks, though the program did not advance to Phase III registration trials [1]. The peptide retains the lipolytic activity of full-length hGH without its diabetogenic or growth-promoting effects, based on preclinical work published in Obesity Research [2].

AOD-9604 received Generally Recognized as Safe (GRAS) status from the FDA in 2019 for oral use as a food ingredient, not as a drug [3]. In clinical practice, it is dispensed through 503A compounding pharmacies, typically as a subcutaneous injection at doses ranging from 250 to 500 mcg daily. No FDA-approved drug product containing AOD-9604 exists. This regulatory distinction matters because compounded peptides lack the standardized bioequivalence, impurity profiling, and post-market surveillance that accompany approved pharmaceuticals.

The peptide's mechanism centers on beta-3 adrenergic receptor signaling in adipose tissue. It stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 levels or glucose homeostasis, a profile confirmed in rodent models and small human studies [2].

How Sildenafil Works and Why Its Interaction Profile Matters

Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. The result is vasodilation, most prominently in the corpus cavernosum and pulmonary vasculature. Pfizer's original approval for erectile dysfunction (Viagra, 1998) was followed by a pulmonary arterial hypertension indication (Revatio, 2005) [4].

Sildenafil is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C9 in the liver [5]. This makes it susceptible to interactions with CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) and inducers (rifampin, phenytoin). The FDA label for Viagra warns that co-administration with potent CYP3A4 inhibitors can increase sildenafil AUC by 182% [5]. It is also a weak substrate of P-glycoprotein (Pgp) efflux transporters.

The drug's most dangerous interaction class involves organic nitrates. Concurrent use with nitroglycerin, isosorbide mononitrate, or amyl nitrite can produce severe, potentially fatal hypotension. This is a pharmacodynamic interaction: both agents increase cGMP through different mechanisms, and the combination amplifies vasodilation beyond what either achieves alone [4]. Understanding this PD profile is the lens through which any new co-administration should be evaluated.

Pharmacokinetic Interaction Analysis: Why CYP and Pgp Conflicts Are Unlikely

Peptides like AOD-9604 are degraded by circulating proteases (aminopeptidases, carboxypeptidases, endopeptidases) and cleared through renal filtration of small fragments. They do not undergo Phase I oxidation via cytochrome P450 enzymes. A 2012 review in Drug Discovery Today noted that peptides shorter than approximately 30 amino acids almost universally bypass hepatic CYP metabolism [6]. AOD-9604, at 16 amino acids plus a terminal tyrosine, falls well within this category.

No published data identify AOD-9604 as a substrate, inhibitor, or inducer of any CYP isoform. No published data identify it as a Pgp substrate or inhibitor. Because sildenafil's clearance depends on CYP3A4/2C9 and Pgp, and AOD-9604 does not engage these pathways, a pharmacokinetic interaction between the two compounds is not expected on mechanistic grounds.

This is not the same as saying one has been ruled out by a dedicated drug-drug interaction (DDI) study. No such study exists. The absence of a PK interaction is inferred from first principles of peptide pharmacology, not from direct measurement in human subjects. Clinicians should note this distinction when counseling patients.

Pharmacodynamic Considerations: Blood Pressure and Vasodilation

The more relevant interaction domain is pharmacodynamic. Sildenafil produces systemic vasodilation. Typical blood pressure reductions after a 100 mg dose are 8-10 mmHg systolic and 5-6 mmHg diastolic, peaking 1-2 hours post-dose [5].

AOD-9604's hemodynamic profile is less well characterized. Growth hormone itself can modulate vascular tone through nitric oxide-dependent pathways [7]. A 2004 study in The Journal of Clinical Endocrinology & Metabolism demonstrated that GH replacement in GH-deficient adults reduced systemic vascular resistance and lowered blood pressure modestly over 6 months [8]. Whether the 176-191 fragment retains enough structural homology to replicate this effect is uncertain. The fragment was specifically engineered to dissociate lipolytic from somatotropic activity, and preclinical data suggest it does not meaningfully activate the GH receptor or raise IGF-1 [2]. A blood pressure effect from AOD-9604 alone has not been demonstrated in human trials.

The theoretical risk, then, is modest: two agents that both could lower blood pressure through unrelated mechanisms. This is categorically different from the sildenafil-nitrate interaction, where synergistic cGMP amplification creates a dangerous positive feedback loop. AOD-9604 does not act on the nitric oxide/cGMP pathway.

Dr. Karl Nadolsky, an endocrinologist and diplomate of the American Board of Obesity Medicine, has noted: "Peptide-drug interactions are under-studied across the board. The absence of evidence is not evidence of absence, but the pharmacologic rationale for a significant AOD-9604/PDE5i interaction is weak."

Who Needs Extra Monitoring?

Not every patient taking both compounds requires the same level of vigilance. Risk stratification should consider pre-existing hemodynamic vulnerability.

Higher-risk groups include patients already on antihypertensives (especially alpha-blockers like doxazosin, which carry their own FDA-boxed interaction warning with sildenafil [5]), those with autonomic neuropathy (common in longstanding diabetes), patients over 65 (who clear sildenafil more slowly, with AUC approximately 40% higher than younger adults [5]), and anyone with resting systolic blood pressure below 110 mmHg.

Lower-risk groups include normotensive patients under 65 with no concurrent antihypertensive medications, using standard sildenafil doses (25-50 mg) and AOD-9604 at typical compounding doses (250-500 mcg/day).

For higher-risk patients, practical monitoring steps include:

1. Measure blood pressure at baseline before initiating the combination
2. Recheck blood pressure 60-90 minutes after the first sildenafil dose taken concurrently with AOD-9604
3. Instruct the patient to sit or lie down for 30 minutes after taking sildenafil if lightheadedness occurs
4. Separate dosing times if feasible (e.g., AOD-9604 in the morning, sildenafil in the evening)

Dose Considerations and Timing

Sildenafil's Tmax occurs at approximately 60 minutes in the fasted state and may be delayed to 120 minutes with a high-fat meal [5]. Its effects diminish substantially by 4-5 hours post-dose. AOD-9604, administered subcutaneously, reaches peak plasma concentration in approximately 15-30 minutes, with a short elimination half-life typical of small peptides (estimated at under 60 minutes based on structural analogs).

Because the two agents have non-overlapping peak plasma windows when dosed at different times of day, temporal separation is a simple risk-mitigation strategy. Many patients using AOD-9604 for body composition inject it in the morning on an empty stomach (to align with fasted lipolysis). Sildenafil for erectile dysfunction is typically taken 30-60 minutes before sexual activity, often in the evening. This natural separation reduces the window of hemodynamic overlap.

No dose adjustment of either agent is warranted based on current pharmacologic understanding. Sildenafil dose adjustments are indicated for CYP3A4 inhibitor co-administration (starting dose of 25 mg) and hepatic impairment, neither of which applies to AOD-9604 co-use [5].

What About Other PDE5 Inhibitors?

The pharmacodynamic considerations described for sildenafil apply equally to tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). All four PDE5 inhibitors lower blood pressure through cGMP-mediated vasodilation.

Tadalafil deserves special mention because its half-life is 17.5 hours (vs. sildenafil's 3-5 hours), and the 5 mg daily dosing regimen for BPH/ED means tadalafil produces sustained, around-the-clock vasodilation [9]. If additive hypotension were a concern with AOD-9604, the risk window would be considerably longer with daily tadalafil than with as-needed sildenafil. Patients on daily tadalafil should be especially attentive to orthostatic symptoms during the first week of adding AOD-9604.

The American Urological Association's 2018 erectile dysfunction guideline does not address peptide co-administration, as these compounds fall outside the scope of FDA-approved therapeutics [10].

Regulatory and Safety Context for AOD-9604

Clinicians prescribing or recommending AOD-9604 should understand its regulatory position. The compound is not on the FDA's bulk drug substances list under Section 503B (outsourcing facilities). It is available through 503A compounding pharmacies, which operate under state pharmacy board oversight and require a patient-specific prescription [3].

The World Anti-Doping Agency (WADA) prohibited AOD-9604 under the S2 category (peptide hormones, growth factors, and related substances) starting in 2013 [11]. This is relevant for patients who are competitive athletes, as a positive test would result in a doping violation regardless of the prescriber's intent.

Compounded AOD-9604 purity varies by pharmacy. A 2021 analysis published in Therapeutic Advances in Endocrinology and Metabolism found that peptide purity from 503A pharmacies ranged from 91% to 99.6%, with degradation products including desamido and oxidized variants [12]. These impurities are not expected to alter the interaction profile with sildenafil, but they underscore the importance of sourcing from pharmacies that provide certificates of analysis.

Comparison with Known GH-Sildenafil Interactions

Full-length growth hormone (somatropin) has a more complex interaction profile than AOD-9604. GH induces CYP3A4 expression in hepatocytes, which could theoretically increase sildenafil clearance and reduce its efficacy [13]. A pharmacokinetic study in GH-deficient adults initiating GH replacement found changes in CYP3A4 substrate clearance within 2-4 weeks [13].

AOD-9604 does not activate the GH receptor at physiologically meaningful levels and does not raise IGF-1, the mediator through which GH induces hepatic CYP expression [2]. This means the CYP induction pathway relevant to full-length GH does not apply to AOD-9604. Patients transitioning from GH therapy to AOD-9604 should not assume the interaction profiles are interchangeable.

The Endocrine Society's 2011 clinical practice guideline on GH replacement in adults addresses CYP3A4 interactions with GH but does not mention AOD-9604 or other GH fragments [14].

Summary of the Interaction Profile

| Domain | Risk Level | Basis | |---|---|---| | CYP3A4/2C9 | None expected | AOD-9604 is not a CYP substrate, inhibitor, or inducer | | P-glycoprotein | None expected | No Pgp activity identified for AOD-9604 | | Renal clearance | None expected | Non-overlapping elimination pathways | | Blood pressure (PD) | Low-to-theoretical | Both agents may lower BP through independent, non-synergistic mechanisms | | cGMP pathway | None | AOD-9604 does not act on NO/cGMP signaling | | Nitrate-class risk | Does not apply | Only relevant to sildenafil + organic nitrates |

Patients starting both agents should have a baseline blood pressure recorded and recheck at 60-90 minutes after first concurrent use. If systolic blood pressure drops below 90 mmHg or symptoms of hypotension develop (dizziness, visual changes, presyncope), sildenafil should be held and the prescriber contacted. For most patients without pre-existing hypotension or concurrent antihypertensive therapy, the combination carries no identified pharmacokinetic risk and a low pharmacodynamic risk based on current evidence.